非均匀剂量优化提升非小细胞肺癌常规分割放疗计划质量
结果显示NHDO在保持靶区覆盖和正常组织约束的同时,提高靶区平均剂量和肿瘤控制概率,并降低部分危及器官剂量。
要点
- NHDO再计划使处方等剂量线从97%降至85%,靶区平均剂量从67 Gy升至73 Gy。
- NHDO降低周围肺、食管和心脏平均剂量,相对降幅分别为6%、14%和15%。
- NHDO使肿瘤控制概率从31.6%翻倍至65.4%。
核心结论
- 在选定患者中,SBRT所用的非均匀剂量优化原则可应用于常规分割放疗,并改善计划质量。
研究设计与样本
- 采用NHDO技术对原CF-RT计划进行再计划,并与HDO计划比较,使用Wilcoxon符号秩检验。
关键数值与推荐
- 所有正常组织剂量约束均得到满足。
临床怎么用
- 对近中央型非小细胞肺癌常规分割放疗,可尝试应用NHDO以增加肿瘤剂量并降低部分危及器官剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nonhomogeneous dose optimization (NHDO) is exploited in stereotactic body radiation therapy (SBRT) to increase dose delivery to the tumor and allow rapid dose falloff to surrounding normal tissues. We investigate changes in plan quality when NHDO is applied to inverse-planned conventionally fractionated radiation therapy (CF-RT) plans in patients with non-small cell lung cancer. METHODS AND MATERIALS: Patients with near-central non-small cell lung cancer treated with CF-RT in 2018 at a single institution were identified. CF-RT plans were replanned using NHDO techniques, including normalizing to a lower isodose line, while maintaining clinically acceptable normal tissue constraints and target coverage. Tumor control probabilities were calculated. We compared delivered CF-RT plans using homogenous dose optimization (HDO) versus NHDO using Wilcoxon signed-rank tests. Median values are reported. RESULTS: Thirteen patients were replanned with NHDO techniques. Planning target volume coverage by the prescription dose was similar (NHDO = 96% vs HDO = 97%, P = .3). All normal-tissue dose constraints were met. NHDO plans were prescribed to a lower-prescription isodose line compared with HDO plans (85% vs 97%, P = .001). NHDO increased mean dose to the planning target volume (73 Gy vs 67 Gy), dose heterogeneity, and dose falloff gradient (P < .03). NHDO decreased mean dose to surrounding lungs, esophagus, and heart (relative reduction of 6%, 14%, and 15%, respectively; P < .05). Other normal tissue objectives improved with NHDO, including total lung V40 and V60, heart V30, and maximum esophageal dose (P < .05). Tumor control probabilities doubled from 31.6% to 65.4% with NHDO (P = .001). CONCLUSIONS: In select patients, NHDO principles used in SBRT optimization can be applied to CF-RT. NHDO results in increased tumor dose, reduction in select organ-at-risk dose objectives, and better maintenance of target coverage and normal-tissue constraints compared with HDO. Our data demonstrate that principles of NHDO used in SBRT can also improve plan quality in CF-RT.
引用
- Hazell SZ, Hales RK, Hrinivich WT, et al. Applying Non-Homogeneous Dose Optimization to Improve Conventionally Fractionated Radiation Plan Quality in Patients with Non-Small Cell Lung Cancer. Pract Radiat Oncol. 2019. PMID: 31252089. doi:10.1016/j.prro.2019.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。